Glenmark Life Sciences Limited
Bookbuilding IPO · NSE, BSE
- Price band
- ₹695-₹720
- Lot size
- 20 shares
- Issue amount
- ₹1,514 cr
- Total subscription
- 0×
- Opens
- 27 Jul 2021
- Closes
- 29 Jul 2021
- Allotment
- 3 Aug 2021
- Listing
- 6 Aug 2021
Offer at a glance
Issue overview
- Issue size
- 2,10,22,222 shares
- Face value
- ₹2 per share
- Minimum investment
- ₹13,900
- Fresh issue
- ₹1,060 cr
- Offer for sale
- ₹454 cr
- Registrar
- Kfin Technologies Limited
- Listing exchange
- NSE, BSE
- Maximum investment
- ₹14,400
- Issue type
- Bookbuilding IPO
- Shares before issue
- 10,78,04,950
- Shares after issue
- 12,25,27,172
Lot sizes
| Category | Lots | Shares | Amount |
|---|---|---|---|
| RETAIL | 1 | 20 | ₹14,400 |
| sHNI | 13 | 280 | ₹2,01,600 |
| bHNI | 70 | 1,400 | ₹10,08,000 |
Share reservation
Subscription & GMP
Subscription by category
Subscription figures are awaiting publication.
GMP history
Financial performance
Company financials
In Lakhs · Reported periods may include interim results.
Company information
Company profile
Incorporated in 2011, Glenmark Life Sciences is a leading manufacturer of active pharmaceutical ingredients (APIs), developing and supplying high-quality products used in treatments for cardiovascular, central nervous system, pain management, diabetes, gastrointestinal disorders, anti-infectives, and other therapeutic areas. The company serves customers in India and exports its products to several international markets including Europe, North America, Latin America, and Japan. It operates four manufacturing facilities located at Ankleshwar and Dahej in Gujarat, and Mohol and Kurkumbh in Maharashtra, with a total annual installed capacity of 725.8 KL as of December 31, 2020.
Strengths
- Leading API Manufacturer: Specializes in APIs for chronic therapies like CVS, CNS, diabetes, and pain management.
- Global Exports: Supplies products across Europe, Latin America, North America, Japan, and other regions.
- Strong Global Relationships: Works closely with leading generic pharmaceutical companies worldwide.
- Strong Financials: Proven track record of consistent financial performance.
- Quality & R&D Focus: High-quality manufacturing supported by robust R&D infrastructure.
Promoters
Glenmark Pharmaceuticals Limited
Registrar & documents
Lead manager
Bofa Securities India Limited, Bob Capital Markets Limited, Dam Capital Advisors Limited, Goldman Sachs (India) Securities Private Limited, Kotak Mahindra Capital Company Limited, SBI Capital Markets Limited
Registrar & contacts
Kfin Technologies Limited
[email protected]Official registrar portal ↗IPO allotment status guide →Registered office
Plot No. 170-172, Chandramouli Industrial Estate, Mohol Bazarpeth, Solapur 413 213,
+91 2189 234456
[email protected]Company website ↗Understanding ALIVUS IPO data
Compare the price band and required investment with the company profile, financial results and offer documents. Subscription figures show reported demand by category; they do not establish the value of the business. GMP is an unofficial indication and can change before listing.